{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:20Z","timestamp":1784822600579,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda Development Center Americas, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00915-1","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:11:55Z","timestamp":1778065915000},"page":"1721-1742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Preferences for Subcutaneous Immunoglobulin\u00a0Among Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Caregivers, and Physicians: A Discrete Choice Experiment"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4864-6658","authenticated-orcid":false,"given":"Min","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam L.","family":"Zichlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsey","family":"Fix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9146-0218","authenticated-orcid":false,"given":"Hakan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Anderson-Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"915_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","volume":"26","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision. J Peripher Nerv Syst. 2021;26:242\u201368.","journal-title":"J Peripher Nerv Syst"},{"key":"915_CR2","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","volume":"268","author":"L Querol","year":"2021","unstructured":"Querol L, Crabtree M, Herepath M, et al. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol. 2021;268:3706\u201316.","journal-title":"J Neurol"},{"key":"915_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1177\/1756285612457215","volume":"5","author":"KC Gorson","year":"2012","unstructured":"Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Ther Adv Neurol Disord. 2012;5:359\u201373.","journal-title":"Ther Adv Neurol Disord"},{"key":"915_CR4","doi-asserted-by":"publisher","first-page":"e635","DOI":"10.1212\/WNL.0000000000008742","volume":"94","author":"M Kapoor","year":"2020","unstructured":"Kapoor M, Spillane J, Englezou C, et al. Thromboembolic risk with IVIg: incidence and risk factors in patients with inflammatory neuropathy. Neurology. 2020;94:e635\u20138.","journal-title":"Neurology"},{"key":"915_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/mus.27356","volume":"64","author":"NA Goyal","year":"2021","unstructured":"Goyal NA, Karam C, Sheikh KA, Dimachkie MM. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2021;64:243\u201354.","journal-title":"Muscle Nerve"},{"key":"915_CR6","unstructured":"European Medicines Agency. Summary of product characteristics: HyQvia 100\u00a0mg\/mL solution for infusion for subcutaneous use. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hyqvia-epar-product-information_en.pdf. Accessed Aug 2025."},{"key":"915_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/bmj.328.7436.360","volume":"328","author":"M Ryan","year":"2004","unstructured":"Ryan M. Discrete choice experiments in health care. BMJ. 2004;328:360\u20131.","journal-title":"BMJ"},{"key":"915_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403\u201313.","journal-title":"Value Health"},{"key":"915_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/mus.24207","volume":"50","author":"A Breiner","year":"2014","unstructured":"Breiner A, Barnett C, Bril V. INCAT disability score: a critical analysis of its measurement properties. Muscle Nerve. 2014;50:164\u20139.","journal-title":"Muscle Nerve"},{"key":"915_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","volume":"76","author":"SI van Nes","year":"2011","unstructured":"van Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology. 2011;76:337\u201345.","journal-title":"Neurology"},{"key":"915_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","volume":"43","author":"JW Shaw","year":"2005","unstructured":"Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203\u201320.","journal-title":"Med Care"},{"key":"915_CR12","unstructured":"MVH Group. The Measurement and Valuation of Health. Final report on the modelling of valuation tariffs. 1995. York: MVH Group, Centre for Health Economics. https:\/\/www.york.ac.uk\/media\/che\/documents\/reports\/MVH%20Final%20Report.pdf. Accessed Aug 2025."},{"key":"915_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s10198-004-0264-z","volume":"6","author":"W Greiner","year":"2005","unstructured":"Greiner W, Claes C, Busschbach JJ, von der Schulenburg JM. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ. 2005;6:124\u201330.","journal-title":"Eur J Health Econ"},{"key":"915_CR14","unstructured":"Reilly Associates. WPAI scoring. http:\/\/www.reillyassociates.net\/wpai_scoring.html. Accessed Aug 2025."},{"key":"915_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12325-020-01540-6","volume":"38","author":"JA Allen","year":"2021","unstructured":"Allen JA, Butler L, Levine T, Haudrich A. A global survey of disease burden in patients who carry a diagnosis of chronic inflammatory demyelinating polyneuropathy. Adv Ther. 2021;38:316\u201328.","journal-title":"Adv Ther"},{"key":"915_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00848-1","author":"S Gingele","year":"2025","unstructured":"Gingele S, Saparilla Pietschmann AC, Jendretzky KF, et al. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: 12\u00a0months results from an observational study. Neurol Ther. 2025. https:\/\/doi.org\/10.1007\/s40120-025-00848-1.","journal-title":"Neurol Ther"},{"key":"915_CR17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/jns.12573","volume":"28","author":"V Bril","year":"2023","unstructured":"Bril V, Hadden RDM, Brannagan TH III, et al. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: the ADVANCE-CIDP 1 randomized controlled trial. J Peripher Nerv Syst. 2023;28:436\u201349.","journal-title":"J Peripher Nerv Syst"},{"key":"915_CR18","unstructured":"United States Food and Drug Administration. Prescribing information: HyQvia 100\u00a0mg\/mL solution for infusion for subcutaneous use. https:\/\/www.shirecontent.com\/PI\/PDFs\/HYQVIA_USA_ENG.pdf. Accessed Aug 2025."},{"key":"915_CR19","volume":"22","author":"AD Sorknaes","year":"2022","unstructured":"Sorknaes AD, Udby S, Juul NK, et al. A review on the effects of shared decision-making (SDM) performed with the purpose of implementing SDM in the ADLIFE project. Int J Integr Care. 2022;22:51.","journal-title":"Int J Integr Care"},{"key":"915_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/cei.12694","volume":"182","author":"M Ponsford","year":"2015","unstructured":"Ponsford M, Carne E, Kingdon C, et al. Facilitated subcutaneous immunoglobulin (fSCIg) therapy\u2014practical considerations. Clin Exp Immunol. 2015;182:302\u201313.","journal-title":"Clin Exp Immunol"},{"key":"915_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/PPA.S303279","volume":"15","author":"PM Overton","year":"2021","unstructured":"Overton PM, Shalet N, Somers F, Allen JA. Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adher. 2021;15:811\u201334.","journal-title":"Patient Prefer Adher"},{"key":"915_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.827305","volume":"13","author":"JM Gonzalez","year":"2022","unstructured":"Gonzalez JM, Ballow M, Fairchild A, Runken MC. Primary immune deficiency: patients\u2019 preferences for replacement immunoglobulin therapy. Front Immunol. 2022;13:827305.","journal-title":"Front Immunol"},{"key":"915_CR23","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2217\/imt-2022-0193","volume":"15","author":"S Tzivelekis","year":"2023","unstructured":"Tzivelekis S, Orange J, Poulos C, et al. Development of a novel shared decision making aid for primary immunodeficiency diseases. Immunotherapy. 2023;15:647\u201356.","journal-title":"Immunotherapy"},{"key":"915_CR24","unstructured":"European Medicines Agency. The patient\u2019s voice in the evaluation of medicines. 2013. https:\/\/www.ema.europa.eu\/en\/documents\/report\/report-workshop-patients-voice-evaluation-medicines_en.pdf. Accessed Aug 2025."},{"key":"915_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40271-020-00449-0","volume":"14","author":"E van Overbeeke","year":"2021","unstructured":"van Overbeeke E, Forrester V, Simoens S, Huys I. Use of patient preferences in health technology assessment: perspectives of Canadian, Belgian and German HTA representatives. Patient. 2021;14:119\u201328.","journal-title":"Patient"},{"key":"915_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.673698","volume":"9","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang Z, Wang Z, Li X, Pang X, Wang S. Application of discrete choice experiment in health care: a bibliometric analysis. Front Public Health. 2021;9:673698.","journal-title":"Front Public Health"},{"key":"915_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2018.07.876","volume":"22","author":"FR Johnson","year":"2019","unstructured":"Johnson FR, Yang JC, Reed SD. The internal validity of discrete choice experiment data: a testing tool for quantitative assessments. Value Health. 2019;22:157\u201360.","journal-title":"Value Health"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00915-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:21Z","timestamp":1784819481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00915-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["915"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00915-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Min Yang, Danni Yang, and Mo Zhou are employees of Analysis Group, Inc., which received funding from Takeda Development Center Americas, Inc. to perform this study. Danni Yang and Mo Zhou are former employees of Analysis Group, Inc. Miriam L Zichlin and Hakan Ay are employees of Takeda Development Center Americas, Inc. and are Takeda shareholders. Chelsey Fix and Lisa Butler are employees of GBS\/CIDP Foundation International. Colin Anderson-Smits is a former employee of Takeda Development Center Americas, Inc. Current affiliation, Gilead Sciences, Foster City, CA, USA.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments, and was granted exemption from a full review by the Pearl Institutional Research Board according to FDA 32 Code of Federal Regulations (CFR) 56.104 and 45CFR46.104(b)(2): (2) Tests, Surveys, Interviews on 01\/11\/2022 (amendment approved on 03\/31\/2022). Informed consent was obtained from participants prior to interviews and online survey completion. Participants received an honorarium payment for their time spent and effort participating in this research.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}